Revenue Breakdown
Composition ()
No data
Revenue Streams
Grifols SA (GRFS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Bioscience, accounting for 85.8% of total sales, equivalent to $1.51B. Other significant revenue streams include Diagnostics and Others/Raw Materials. Understanding this composition is critical for investors evaluating how GRFS navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Grifols SA maintains a gross margin of 39.33%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 18.88%, while the net margin is 7.69%. These profitability ratios, combined with a Return on Equity (ROE) of 6.87%, provide a clear picture of how effectively GRFS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, GRFS competes directly with industry leaders such as RYTM and BLTE. With a market capitalization of $6.19B, it holds a significant position in the sector. When comparing efficiency, GRFS's gross margin of 39.33% stands against RYTM's 91.61% and BLTE's N/A. Such benchmarking helps identify whether Grifols SA is trading at a premium or discount relative to its financial performance.
